Overview


According to FutureWise analysis the market for solid tumor therapeutics is expected to register a CAGR of 12.7% from 2023-2031.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Solid Tumor Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Solid Tumor Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Hoffmann-La Roche Ltd
  • Johnson and Johnson
  • Novartis
  • AstraZeneca plc
  • Biogen Idec, Inc
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Kyowa Hakko Kirin Co., Ltd.
  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Bristol Myers Squibb Company
  • Amgen Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Other Cancer Types

By Type of Therapy

  • Chemotherapy
  • Hormone therapy
  • Immunotherapy
  • Targeted therapy

By Drug Type

  • Carboplatin
  • Cisplatin
  • Gemcitabine
  • Paclitaxel
  • Doxorubicin
  • Bevacizumab
  • Erlotinib
  • Sunitinib
  • Everolimusa
  • Other Drug Types

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  •  Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Solid Tumor Therapeutics Market By Cancer Types, By Type of Therapy, By Drug Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Application launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Solid Tumor Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Solid Tumor Therapeutics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Solid Tumor Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Solid Tumor Therapeutics Market, By Cancer Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Cervical Cancer
        6. Ovarian Cancer
        7. Other Cancer Types

  • 8.   Solid Tumor Therapeutics Market, By Type of Therapy Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chemotherapy
        2. Hormone therapy
        3. Immunotherapy
        4. Targeted therapy

  • 9.   Solid Tumor Therapeutics Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Carboplatin
        2. Cisplatin
        3. Gemcitabine
        4. Paclitaxel
        5. Doxorubicin
        6. Bevacizumab
        7. Erlotinib
        8. Sunitinib
        9. Everolimusa
        10. Other Drug Types

  • 10.   North America Solid Tumor Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Solid Tumor Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Solid Tumor Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Solid Tumor Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Hoffmann-La Roche Ltd
         1.1. Company Overview
         1.2. Application Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Johnson and Johnson
         2.1. Company Overview
         2.2. Application Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis
         3.1. Company Overview
         3.2. Application Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca plc
         4.1. Company Overview
         4.2. Application Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Biogen Idec, Inc
         5.1. Company Overview
         5.2. Application Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Boehringer Ingelheim GmbH
         6.1. Company Overview
         6.2. Application Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GlaxoSmithKline plc
         7.1. Company Overview
         7.2. Application Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eli Lilly and Company
         8.1. Company Overview
         8.2. Application Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Kyowa Hakko Kirin Co., Ltd.
         9.1. Company Overview
         9.2. Application Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Abbott Laboratories, Inc.
         10.1. Company Overview
         10.2. Application Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Baxter International, Inc.
         11.1. Company Overview
         11.2. Application Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Bristol Myers Squibb Company
         12.1. Company Overview
         12.2. Application Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Amgen Inc
         13.1. Company Overview
         13.2. Application Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients